Dr. Daniel Petrylak on the Role of Enzalutamide in Prostate Cancer

feeds has 409 videos Subscribe Here

Description: Daniel P. Petrylak, MD, director, Prostate and Genitourinary Cancer Program, co-director, Signal Transduction Research Program, at the Smilow Cancer Center at Yale-New Haven, discusses his excitement over the recent approval of enzalutamide (Xtandi) for patients with metastatic castration-resistant prostate cancer (mCRPC) who have been previously treated with docetaxel and hormonal therapy.

For more prostate cancer resources, visit
Shared By : feeds
Posted on : 11/05/12
Added : 5 years ago
Category : Prostate Cancer

More From feeds

Nothing found.